BioSpace News Archive

Wilmington, Delaware, United States, Transparency Market Research Inc.: Nanoparticles fall in the range of sizes 1nm to 100nm and are used in multiple applications such as optical, electronic, and biomedical sectors.

Pharming Group N.V. announces that the European Medicines Agency’s Committee for Medicinal Products for Human Use has granted an accelerated assessment for the Marketing Authorisation Application for leniolisib.

Ipsen and Marengo Therapeutics, Inc. announced a strategic partnership to advance two of Marengo’s preclinical STAR platform-generated candidates into the clinic.

The diagnostics company SphingoTec GmbH announces new findings that support the clinical value of the biomarker bio-ADM for triaging sepsis patients in ED, exceeding the prognostic performance of routine biomarkers.

Eledon Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has cleared the company’s Investigational New Drug application to evaluate tegoprubart for the prevention of organ rejection in patients receiving a kidney transplant.

Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, announced that company management will participate in the following conference and invited investors to participate by webcast.

NanOlogy LLC, a clinical-stage interventional oncology drug company, announced that results from a clinical trial of Large Surface Area Microparticle Docetaxel in High-Risk Non-Muscle Invasive Bladder Cancer have been published in The Journal of Urology®.

Nutriband Inc. announced that it has received a Notice of Allowance from the Canadian Intellectual Property Office for its patent application, CA 2937649, entitled “Abuse and Misuse Deterrent Transdermal Systems,” that protects its AVERSA™ transdermal abuse deterrent technology.

GENEVA, Switzerland – August 1, 2022 – ObsEva SA, a biopharmaceutical company developing novel therapies for women’s health, announced the early retirement of $31 million in debt that was part of amounts owed to certain funds and accounts managed by JGB Management, Inc. pursuant to the Company’s Securities Purchase Agreement with JGB.

Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that John Northcott has joined the company in a newly created position of Chief Commercial Officer (CCO).